SANGAMO THERAPEUTICS, INC 8-K

What Happened
Sangamo Therapeutics, Inc. announced its financial results for the year ended December 31, 2025 via a press release dated March 30, 2026. The company filed an Form 8‑K (Item 2.02) to furnish that press release (Exhibit 99.1), which the filing states is incorporated by reference. The filing was signed by Scott B. Willoughby, Chief Legal Officer and Corporate Secretary.

Key Details

• Filing date: March 30, 2026 (Form 8‑K, Item 2.02).
• Reporting period: year ended December 31, 2025 (financial results announced in the press release).
• Exhibit furnished: Exhibit 99.1 (press release) and Interactive XBRL cover page (Exhibit 104).
• Authorized signer: Scott B. Willoughby, Chief Legal Officer and Corporate Secretary.

Why It Matters
This 8‑K gives investors timely access to Sangamo’s full‑year 2025 financial results (earnings, revenue, and other financial condition items will be in the press release). Review the press release (Exhibit 99.1) and other SEC filings for the specific figures—those details can affect valuation, analyst expectations, and trading decisions.